- Merck & Co Inc (NYSE:MRK) and its collaborating partner Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials of molnupiravir in non-hospitalized COVID-19 patients.
- The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases.
- In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in 2H of 2021.
- As reported earlier, the percentage of hospitalized patients or died in Part 1 of the study was lower in the combined molnupiravir-treated groups versus the placebo arm.
- The most significant overall magnitude of the antiviral effect was observed in the 800 mg dose compared with the 200 mg and 400 mg doses.
- Price Action: MRK shares traded lower by 0.14% at $77.88 premarket on the last check Monday.
Cantor Fitzgerald Downgrades iBio to Neutral, Lowers Price Target to $0.17
Cantor Fitzgerald analyst Kristen Kluska downgrades iBio (AMEX:IBIO) from Overweight to Neutral and lowers the price target from $2.5 to $0.17.
